|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Exp. Med.,
Volume 189, Number 5, March 1, 1999 767-778
By


From the * Ludwig Institute for Cancer Research, Université Catholique de Louvain 74.59, B-1200
Brussels, Belgium; the MAGE-type genes are expressed by many tumors of different histological types and not by
normal cells, except for male germline cells, which do not express major histocompatibility
complex (MHC) molecules. Therefore, the antigens encoded by MAGE-type genes are strictly
tumor specific and common to many tumors. We describe here the identification of the first
MAGE-encoded epitopes presented by histocompatibility leukocyte antigen (HLA) class II
molecules to CD4+ T lymphocytes. Monocyte-derived dendritic cells were loaded with a
MAGE-3 recombinant protein and used to stimulate autologous CD4+ T cells. We isolated
CD4+ T cell clones that recognized two different MAGE-3 epitopes, MAGE-3114-127 and
MAGE-3121-134, both presented by the HLA-DR13 molecule, which is expressed in 20% of
Caucasians. The second epitope is also encoded by MAGE-1, -2, and -6. Our procedure
should be applicable to other proteins for the identification of new tumor-specific antigens presented by HLA class II molecules. The knowledge of such antigens will be useful for evaluation
of the immune response of cancer patients immunized with proteins or with recombinant viruses carrying entire genes coding for tumor antigens. The use of antigenic peptides presented
by class II in addition to peptides presented by class I may also improve the efficacy of therapeutic antitumor vaccination.
Laboratory of Physiology, Medical School, Free University of Brussels, B-1070
Brussels, Belgium; and § Erasmus University Rotterdam, Department of Surgical Oncology, University
Hospital Rotterdam, Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
This article has been cited by other articles:
| TABLE OF CONTENTS |
|